BINV.ST Stock - BioInvent International AB (publ)
Unlock GoAI Insights for BINV.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $44.69M | $71.46M | $326.13M | $19.38M | $147.37M |
| Gross Profit | $44.69M | $71.46M | $326.13M | $19.38M | $147.37M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-471,059,000 | $-369,942,000 | $-50,921,000 | $-278,350,000 | $-75,474,000 |
| Net Income | $-429,375,000 | $-330,304,000 | $-34,085,000 | $-278,961,000 | $-76,669,000 |
| Net Margin | -960.9% | -462.2% | -10.5% | -1439.1% | -52.0% |
| EPS | $-6.53 | $-5.02 | $-0.55 | $-5.15 | $-2.67 |
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.
Visit WebsiteEarnings History & Surprises
BINV.STEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | — | — | — | — |
Q4 2025 | Oct 29, 2025 | — | $-1.96 | — | — |
Q3 2025 | Aug 26, 2025 | — | $0.59 | — | — |
Q2 2025 | Apr 29, 2025 | — | $-1.77 | — | — |
Q1 2025 | Feb 27, 2025 | — | $-1.78 | — | — |
Q4 2024 | Oct 31, 2024 | — | $-1.48 | — | — |
Q3 2024 | Aug 29, 2024 | — | $-2.09 | — | — |
Q2 2024 | Apr 24, 2024 | — | $-1.18 | — | — |
Q1 2024 | Feb 22, 2024 | $-1.11 | $-1.48 | -33.6% | ✗ MISS |
Q4 2023 | Oct 26, 2023 | $-1.24 | $-1.08 | +12.9% | ✓ BEAT |
Q3 2023 | Aug 30, 2023 | $-1.27 | $-1.34 | -5.8% | ✗ MISS |
Q2 2023 | Apr 26, 2023 | $-1.27 | $-1.12 | +11.8% | ✓ BEAT |
Q1 2023 | Feb 22, 2023 | $-1.25 | $-1.21 | +3.2% | ✓ BEAT |
Q4 2022 | Oct 27, 2022 | $-1.17 | $-1.00 | +14.5% | ✓ BEAT |
Q3 2022 | Aug 25, 2022 | $-1.16 | $2.86 | +346.6% | ✓ BEAT |
Q2 2022 | Apr 27, 2022 | $-1.67 | $-1.16 | +30.5% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $-1.37 | $-1.35 | +1.5% | ✓ BEAT |
Q4 2021 | Oct 28, 2021 | $-1.71 | $-1.07 | +37.4% | ✓ BEAT |
Q3 2021 | Aug 26, 2021 | $-1.13 | $-0.98 | +13.3% | ✓ BEAT |
Latest News
Frequently Asked Questions about BINV.ST
What is BINV.ST's current stock price?
What is the analyst price target for BINV.ST?
What sector is BioInvent International AB (publ) in?
What is BINV.ST's market cap?
Does BINV.ST pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BINV.ST for comparison